Latent Labs has launched Latent-Y, an AI agent that autonomously designs therapeutic antibodies from text prompts, reducing weeks of expert work to hours. The system is powered by Latent-X2, the company's frontier model for drug-like antibody and peptide design. Latent-Y operates independently, analysing target molecules, identifying viable epitopes, designing antibody candidates and validating them computationally. Scientists can run the agent fully autonomously or pause at each stage for review. The London and San Francisco-based company has demonstrated lab-validated results across three antibody design campaigns, including epitope discovery yielding nanomolar-affinity binders. User studies showed PhD-level experts completed design campaigns 56 times faster using Latent-Y compared to independent expert estimates. The platform is now available to selected partners through the Latent Labs platform.

GenScript Biotech Corporation has announced its role as wet-lab partner for Latent Labs' Latent-X2, a next-generation AI model that designs antibodies and peptides with drug-like properties. GenScript provides high-throughput expression, purification and functional testing of AI-generated molecules, enabling rapid iteration between computational predictions and biological performance. Using its TurboCHO™ High Throughput Platform and cell-free expression systems, GenScript screens AI-designed antibodies, minibinders and peptides to compare candidates and collect data on developability and binding. This reduces reliance on iterative wet-lab optimisation. The collaboration addresses a key industry challenge by accelerating timelines whilst improving likelihood of clinical success. Founded in 2002, GenScript supports over 200,000 customers across 100-plus countries with a team of 5,500-plus employees.